Clinical Comprehensive Guide: Elastofibroma Dorsi (EFD)

1. Comprehensive Introduction & Overview

Elastofibroma dorsi (EFD) is a rare, benign, slow-growing, non-encapsulated soft-tissue tumor. Despite its classification as a "tumor," current clinical consensus suggests it represents a reactive fibroelastic proliferation rather than a true neoplasm. It typically manifests as a poorly defined mass located in the subscapular region, specifically between the thoracic wall and the scapula.

First described by Jarvi and Saxen in 1961, EFD is historically notable for its predilection for elderly populations, particularly women, and its strong association with repetitive mechanical friction. While often asymptomatic, it can cause significant morbidity through scapular snapping, discomfort, and restricted range of motion. Due to its deep location and characteristic imaging appearance, it is often misdiagnosed as a malignant sarcoma, making clinical awareness vital for orthopedic and musculoskeletal specialists.

2. Deep-Dive: Etiology and Pathophysiology

The Mechanics of Proliferation

The prevailing theory regarding the etiology of EFD is the mechanical friction hypothesis. The lesion occurs at the interface where the scapula moves against the ribs. Chronic, repetitive micro-trauma at this site is thought to stimulate fibroblastic activity.

• Vascular Insufficiency: Some studies suggest that repetitive trauma causes intermittent ischemia of the subscapular tissues, which triggers a reparative process that goes awry, resulting in the overproduction of abnormal elastic fibers.
• Genetic Predisposition: While largely reactive, there is evidence of familial clustering in a small subset of patients, suggesting a genetic susceptibility to abnormal fibroblastic response to mechanical stress.
• Enzymatic Activity: The lesion is characterized by an increase in lysosomal enzymes, which may contribute to the degradation of elastic fibers, leading to the accumulation of abnormal, fragmented, and thickened elastic material.

Histopathological Characteristics

Under microscopic examination, EFD is pathognomonic. It consists of:
1. Abundant Collagenous Stroma: Interspersed with adipose tissue.
2. Abnormal Elastic Fibers: These are the hallmark—thickened, fragmented, "beaded," or "globular" elastic fibers that stain intensely with Verhoeff-van Gieson or Orcein stains.
3. Lack of Encapsulation: Unlike true lipomas or fibromas, EFD infiltrates the surrounding fat and muscle, making surgical excision technically challenging.

3. Clinical Staging and Presentation

Standard Presentation

EFD typically presents as a firm, non-tender, slow-growing mass in the infrascapular region. Patients frequently report:
* Scapular Snapping/Clunking: A sensation of the scapula "catching" on the mass during arm abduction or elevation.
* Back Discomfort: Often described as a dull ache or sensation of fullness.
* Asymmetry: In bilateral cases, the patient may notice a widening of the back profile.

Clinical Staging/Grading (Modified)

While there is no universally accepted formal "staging" system like malignant tumors, clinicians often categorize EFD based on clinical impact:

4. Differential Diagnosis

Distinguishing EFD from malignant soft tissue tumors is the primary clinical objective. The differential includes:

• Liposarcoma: The most critical exclusion. Usually deeper, more heterogeneous, and potentially aggressive.
• Desmoid Tumor: More aggressive, infiltrative, and prone to local recurrence.
• Fibromatosis: Often presents with more rapid growth and different imaging characteristics.
• Metastatic Disease: Must be considered in patients with a known history of primary malignancy (e.g., breast, lung).
• Soft Tissue Sarcoma (General): Any mass that is rapidly growing or fixed to deep structures requires biopsy.

5. Diagnostic Testing Protocols

Imaging Modalities

Imaging is the cornerstone of EFD diagnosis. In many cases, the imaging appearance is so specific that biopsy is not required.

1. Computed Tomography (CT): Shows a mass with attenuation similar to skeletal muscle, interspersed with fat streaks. The lack of distinct margins is characteristic.
2. Magnetic Resonance Imaging (MRI): The gold standard.
   • T1-weighted: Shows alternating layers of intermediate signal (fibrous tissue) and high signal (adipose tissue).
   • T2-weighted: Typically shows low signal intensity due to the high fibrous content.
   • Contrast: Minimal to no enhancement, which helps distinguish it from more vascular malignant lesions.
3. Ultrasound (US): Useful for initial screening in thin patients; shows a heterogeneous, multi-layered appearance.

Biopsy Recommendations

Biopsy is generally reserved for:
* Lesions that show atypical imaging features (e.g., rapid growth, central necrosis).
* Patients with a history of malignancy where metastasis is suspected.
* Core needle biopsy is preferred over fine-needle aspiration (FNA) due to the dense fibrous nature of the tissue.

6. Risks, Side Effects, and Contraindications

Surgical Risks

Surgical excision (subscapular bursectomy/resection) is the definitive treatment but carries risks:
* Seroma Formation: The most common complication (up to 40% of cases) due to the large dead space created after excision.
* Hematoma: Requires meticulous hemostasis.
* Nerve Injury: Risk of injury to the long thoracic nerve or dorsal scapular nerve, leading to scapular winging.
* Recurrence: Very rare, usually due to incomplete resection.

Contraindications

• Asymptomatic status: If the mass is not causing pain or functional decline, surgery is rarely indicated due to the risks of post-operative morbidity.
• High surgical risk: In elderly, frail patients, the risks of general anesthesia and prolonged recovery may outweigh the benefits of removing a benign, slow-growing mass.

7. Long-Term Prognosis

The prognosis for EFD is excellent. It is a benign, non-metastasizing process.
* Post-Excision: Once the mass is removed, the probability of recurrence is extremely low.
* Functional Recovery: Most patients return to full range of motion within 6–12 weeks, provided physical therapy is initiated to restore scapulothoracic rhythm.
* Quality of Life: Patients who undergo surgery for symptomatic EFD report significant improvement in daily activities and reduction in scapular snapping symptoms.

8. Massive FAQ Section

1. Is Elastofibroma Dorsi a type of cancer?

No. It is a benign, reactive fibroelastic proliferation. It does not metastasize and is not considered a true neoplasm.

2. Can EFD disappear on its own?

Extremely unlikely. Because it is composed of dense fibrous tissue and elastic fibers, it does not undergo spontaneous regression.

3. Is surgery always necessary?

No. If the patient is asymptomatic, the standard of care is "watchful waiting" or observation. Surgery is reserved for patients experiencing pain or significant functional limitation.

4. Why is it usually found in the back?

The subscapular area is the site of constant friction between the scapula and the thoracic cage. This mechanical stress is the primary driver for the formation of the lesion.

5. Does EFD affect both sides of the body?

Yes, it can be bilateral in approximately 10% to 30% of patients, though it often presents asymmetrically.

6. What is the most common age of onset?

It is most commonly diagnosed in patients over the age of 50, with a peak incidence in the 60s and 70s.

7. Does it grow quickly?

No. EFD is characterized by very slow growth. Rapid growth should always raise clinical suspicion for a more aggressive process like a sarcoma.

8. What is the biggest complication after surgery?

The formation of a seroma (a collection of fluid) in the surgical site is the most frequent complication, often managed with drains and compression garments.

9. Can MRI confirm the diagnosis without a biopsy?

In many cases, yes. The characteristic "striped" appearance on MRI, matching the density of muscle and fat, is highly diagnostic for experienced radiologists.

10. How long is the recovery after an excision?

Recovery typically involves a few days in the hospital, followed by 4–8 weeks of physical therapy focused on scapular stabilization and restoring shoulder range of motion.

9. Conclusion for Clinical Practice

Elastofibroma dorsi remains a fascinating intersection of mechanical repetitive stress and biological tissue response. For the orthopedic specialist, the key to management is accurate recognition. By leveraging high-quality MRI imaging and maintaining a low threshold for conservative management in asymptomatic patients, clinicians can avoid unnecessary, high-morbidity surgical interventions. When surgery is required, meticulous attention to dead-space management is the single most important factor in ensuring a successful outcome.

Disclaimer: This guide is for educational purposes for healthcare professionals and does not constitute formal medical advice. Always correlate findings with clinical examination and imaging reports.